Changes of plasma fibrinolytic markers in idiopathic membranous nephropathy disease progress

doi:10.3969/j.issn.1673-8640.2020.01.006

Abstract

Abstract:

Objective To analyze the difference of plasma fibrinolytic markers in different chronic kidney disease（CKD） stages of idipothic membranous nephropathy（IMN）. Methods A total of 200 IMN patients（IMN group,including 103 cases of CKD1,53 cases of CKD2,30 cases of CKD3 and 14 cases of CKD4-5） and 97 healthy subjects（healthy control group） were enrolled. The levels of plasmin-α2 antiplasmin complex（PIC）,tissue plasminogen activator-inhibitor 1 complex（tPAIC）,fibrinogen（Fib）,fibrin degradation product（FDP ） and D-dimer（DD） were determined. Results Fib,FDF,DD and PIC in IMN group were higher than those in healthy control group（P<0.01）,and tPAIC level was lower. With different CKD stages,Fib and tPAIC levels had statistical significance（P<0.05）. With the increasing of CKD stages,Fib levels were increased,and tPAIC levels were decreased. For Fib and tPAIC,there was statistical significance between CKD1 and CKD3,CKD4-5 （P<0.05）,and there was no statistical significance for FDP,DD and PIC with different CKD stages（P>0.05）. Conclusions IMN patients have poor fibrinolytic system function,and it is easy to form thromboembolia. Fib and tPAIC are related to disease stage,which can be used as the indicators of IMN disease progress and thromboembolia prevention monitoring.

Key words: Fibrinolytic marker, Thromboembolia, Idiopathic membranous nephropathy

CLC Number:

R446.1

LI Zhen, LI Zhen, CHEN Weiqin, YIN Hongmei, HU Xiaobo. Changes of plasma fibrinolytic markers in idiopathic membranous nephropathy disease progress[J]. Laboratory Medicine, 2020, 35(1): 25-28.

Figures/Tables 2

References 20

[1]	WU Y Q,WANG Z,XU H F,et al.Frequency of primary glomerular disease in northeastern China[J]. Braz J Med Biol Res,2011,44(8):810-813.
[2]	陈香美. 临床诊疗指南-肾脏病学分册[M]. 北京:人民卫生出版社,2011:23-29.
[3]	LIONAKI S,DEREBAIL V K,HOGAN S L,et al.Venous thromboembolism in patients with membranous nephropathy[J]. Clin J Am Soc Nephrol,2012,7(1):43-51.
[4]	谌贻璞. 慢性肾脏病的定义与分期-从KDOQI到KDIGO:贡献与问题[J]. 临床肾脏病杂志,2011,11(1):4-6.
[5]	PONTICELLI C,PASSERINI P.Management of idiopathic membranous nephropathy[J]. Expert Opin Pharmacother,2010,11(13):2163-2175.
[6]	AL-AZZAWI H F,OBI O C,SAFI J,et al. Nephrotic syndrome-induced thromboembolism in adults[J]. Int J Crit Illn Inj Sci,2016,6(2):85-88.
[7]	KERLIN B A,AYOOB R,SMOYER W E.Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease[J]. Clin J Am Soc Nephrol,2012,7(3):513-520.
[8]	付阳,刘玉梅,金亚雄,等. 凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究[J]. 中国肺癌杂志,2018,21(8):583-587.
[9]	MOORE H B,MOORE E E,GENZALEZ E,et al.Hyperfibrinolysis,physiologic fibrinolysis,and fibrinolysis shutdown:the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy[J]. J Trauma Acute Care Surg,2014,77(6):811-817.
[10]	NIELSEN V G,MATIKA R W,LEY M L,et al.Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast,lung,pancreas and colon cancer[J]. Blood Coagul Fibrinolysis,2014,25(3):248-253.
[11]	高芳,张云娜,赵乃蕊,等. 不同程度亚临床甲状腺功能减退症患者止凝血相关指标变化的研究[J]. 检验医学,2018,33(2):110-114.
[12]	POGGESI A,PASI M,PESCINI F,et al.Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease:a review[J]. J Cereb Blood Flow Metab,2016,36(1):72-94.
[13]	陈文欣,李强,薛赢俊,等. 恶性肿瘤患者凝血-纤溶系统标志物检测及其临床意义[J]. 检验医学,2018,33(8):722-726.
[14]	弭雪. 出凝血分子标志物在弥散性血管内凝血中的动态变化及意义[D]. 青岛:山东大学,2017.
[15]	黄智明. 血浆纤维蛋白原测定诊断脑血栓的价值探究[J]. 当代医学,2017,23(33):59-61.
[16]	魏连波. 肾病综合征高凝状态形成机制与中医治疗[J].中华肾病研究电子杂志,2017,6(4):169-172.
[17]	HAN L,LIU X,LI H,et al.Blood coagulation parameters and platelet indices:changes in normal and preeclamptic pregnancies and predictive values for preeclampsia[J]. PLoS One,2014,9(12):e114488.
[18]	CHEN X W,LIU W T,WANG Y X,et al.Cyclopropanyldehydrocostunolide LJ attenuates high glucose-induced podocyte injury by suppressing RANKL/RANK-mediated NF-κB and MAPK signaling pathways[J]. J Diabetes Complications,2016,30(5):760-769.
[19]	张鸿,梁顺,杜玥,等. 核因子κB受体活化因子通过TRPC6-NFATc1信号通路介导足细胞损伤[J]. 实用医学杂志,2019,35(1):25-29.
[20]	王宏天. 纤维蛋白原与肾脏疾病[J]. 肾脏病与透析肾移植杂志,2016,25(5):466-469.

组别	例数	Fib/（g/L）	FDP/（μg/mL）	DD/（mg/L）	PIC/（μg/mL）	tPAIC/（ng/mL）
IMN组	200	3.70±1.15	2.30（1.20,3.90）	0.46（0.25,0.97）	0.96±0.70	6.64±3.90
健康对照组	97	2.72±0.70	0.73（0.00,1.69）	0.19（0.13,0.29）	0.50±0.21	8.18±3.90
P值		<0.01	<0.01	<0.01	<0.01	<0.01

组别	例数	Fib/（g/L）	FDP/（μg/mL）	DD/（mg/L）	PIC/（μg/mL）	tPAIC/（ng/mL）
IMN组	200	3.70±1.15	2.30（1.20,3.90）	0.46（0.25,0.97）	0.96±0.70	6.64±3.90
健康对照组	97	2.72±0.70	0.73（0.00,1.69）	0.19（0.13,0.29）	0.50±0.21	8.18±3.90
P值		<0.01	<0.01	<0.01	<0.01	<0.01

分别	例数	Fib/（g/L）	FDP/（μg/mL）	DD/（mg/L）	PIC/（μg/mL）	tPAIC/（ng/mL）
CKD1期	103	3.62±1.10	2.30（1.30,4.00）	0.42（0.24,0.95）	1.09±0.86	8.20±3.54
CKD2期	53	3.97±1.13	2.70（1.13,3.90）	0.57（0.24,1.03）	1.04±0.65	7.70±4.77
CKD3期	30	4.34±1.51^*	1.90（1.13,4.58）	0.48（0.32,0.84）	1.17±0.70	6.34±4.28^*
CKD4~5期	14	4.69±1.57^*	3.40（1.85,4.70）	0.60（0.30,1.99）	1.15±0.69	6.07±4.66^*
P值		0.008	0.771	0.533	0.907	0.011

分别	例数	Fib/（g/L）	FDP/（μg/mL）	DD/（mg/L）	PIC/（μg/mL）	tPAIC/（ng/mL）
CKD1期	103	3.62±1.10	2.30（1.30,4.00）	0.42（0.24,0.95）	1.09±0.86	8.20±3.54
CKD2期	53	3.97±1.13	2.70（1.13,3.90）	0.57（0.24,1.03）	1.04±0.65	7.70±4.77
CKD3期	30	4.34±1.51^*	1.90（1.13,4.58）	0.48（0.32,0.84）	1.17±0.70	6.34±4.28^*
CKD4~5期	14	4.69±1.57^*	3.40（1.85,4.70）	0.60（0.30,1.99）	1.15±0.69	6.07±4.66^*
P值		0.008	0.771	0.533	0.907	0.011